Research programme: MM 302 companion diagnostics - Merrimack Pharmaceuticals

Drug Profile

Research programme: MM 302 companion diagnostics - Merrimack Pharmaceuticals

Alternative Names: 64Cu-Liposomal PET Agent - Merrimack Pharmaceuticals; DX-929; MM-DX-929

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Merrimack Pharmaceuticals
  • Class Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Image enhancers; Positron-emission tomography enhancers; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Breast cancer; Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Breast-cancer(Diagnosis) in USA (IV)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours(Diagnosis) in USA (IV)
  • 11 Dec 2012 Pharmacodynamics/pharmacokinetics data from a preclinical study in Breast cancer (Diagnosis) released by Merrimack Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top